Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma: a Randomized Phase II Trial

NCT07347210 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT07347210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07347210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma: a Randomized Phase II Trial
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
July 31, 2029
Enrollment
98 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

primary glioblastoma